Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
Subscribe To Our Newsletter & Stay Updated
